指南与共识乳腺病理细胞病理与分子病理

ASCO/CAP乳腺癌HER2检测指南聚焦更新

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
指南 / 共识 · Arch Pathol Lab Med · 2018-05-30

本文为ASCO/CAP关于乳腺癌HER2检测指南的聚焦更新,基于信号方法由专家组审查文献和调研结果,更新了IHC 2+定义、核心针活检阴性后切除标本检测建议及双探针ISH少见模式(约5%)的判读算法,强调ISH与IHC联合解读。

要点

  • IHC 2+定义为>10%肿瘤细胞弱至中等完整膜染色。
  • 核心针活检HER2阴性时,可根据临床标准在切除标本复查(非必须)。
  • 双探针ISH第2-4组需联合IHC复核以确定HER2状态。

核心结论

  • 更新了乳腺癌HER2检测的关键推荐,包括IHC 2+定义和ISH少见模式的判读。
  • 对双探针ISH第2-4组,需联合IHC复核以准确判定HER2阳性或阴性。

研究设计与样本

  • 基于信号方法,专家组审查已发表文献和研究调研结果。
  • 纳入2015年通过通信解决的两条推荐。

主要发现

  • IHC 2+定义为浸润性乳腺癌中>10%肿瘤细胞呈现弱至中等完整膜染色。
  • 核心针活检HER2阴性时,基于特定临床标准可在切除标本复查(非必须)。
  • 双探针ISH少见模式约占5%,分为ISH第2、3、4组。

关键数值与推荐

  • ISH第2组:HER2/CEP17比值≥2.0且平均HER2拷贝数<4.0信号/细胞。
  • ISH第3组:HER2/CEP17比值<2.0且平均HER2拷贝数≥6.0信号/细胞。
  • ISH第4组:HER2/CEP17比值<2.0且平均HER2拷贝数≥4.0且<6.0信号/细胞。
  • 双探针ISH第2-4组需联合IHC复核。
  • 单探针ISH检测实验室应将IHC复核纳入所有单探针ISH结果的判读。

临床怎么用

  • 按更新定义判读IHC 2+,避免过度或不足诊断。
  • 核心针活检阴性时,结合临床标准决定是否在切除标本复查HER2。
  • 双探针ISH少见模式需联合IHC复核以确定HER2状态。
  • 单探针ISH检测应常规联合IHC复核。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE.—: To update key recommendations of the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. METHODS.—: Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to update the recommendations. RECOMMENDATIONS.—: Two recommendations addressed via correspondence in 2015 are included. First, immunohistochemistry (IHC) 2+ is defined as invasive breast cancer with weak to moderate complete membrane staining observed in >10% of tumor cells. Second, if the initial HER2 test result in a core needle biopsy specimen of a primary breast cancer is negative, a new HER2 test may (not "must") be ordered on the excision specimen based on specific clinical criteria. The HER2 testing algorithm for breast cancer is updated to address the recommended workup for less common clinical scenarios (approximately 5% of cases) observed when using a dual-probe ISH assay. These scenarios are described as ISH group 2 ( HER2/chromosome enumeration probe 17 [CEP17] ratio ≥2.0; average HER2 copy number <4.0 signals per cell), ISH group 3 ( HER2/CEP17 ratio <2.0; average HER2 copy number ≥6.0 signals per cell), and ISH group 4 ( HER2/CEP17 ratio <2.0; average HER2 copy number ≥4.0 and <6.0 signals per cell). The diagnostic approach includes more rigorous interpretation criteria for ISH and requires concomitant IHC review for dual-probe ISH groups 2 to 4 to arrive at the most accurate HER2 status designation (positive or negative) based on combined interpretation of the ISH and IHC assays. The Expert Panel recommends that laboratories using single-probe ISH assays include concomitant IHC review as part of the interpretation of all single-probe ISH assay results.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018. PMID: 29846104. doi:10.5858/arpa.2018-0902-SA

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。